Search

We here report final results of a phase II/III prospective study that evaluated in Multiple Myeloma the use of on-demand plerixafor (PLX) added to mobilizing chemotherapy for patients showing predictive signs of mobilization failure. A total of 111 patients with MM were registered, all received cyclophosphamide 4 g/m2and granulocyte colony-stimulating factor (G-CSF). Overall, a successful CD34+ cell mobilization was achieved in 97.2% (108/111) of patients. Minimum harvest (≥2.0 × 106CD34+ cells/kg) was achieved in 97.2% (108/111) and optimal harvest success (≥4.0 × 106CD34+ cells/kg) was achieved in 84.6% (94/111). Multivariate analysis showed that patients who received on-demand PLX treatment had significantly higher likelihoods of successfully achieving both the minimal (p = .006) and optimal harvest (p = .05) in respect to a historical control group mobilized without any PLX. The incremental cost-effectiveness ratio, for each 1% increase in probability of achieving a successful minimal harvest, was€40.6 per patient. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 52-years-old male patient diagnosed with acute myeloid leukemia with normal karyotype. Topics discussed include development of resistance to drugs such as citarabine and etoposide, development of polycythemiaduring iron chelating therapy (ICT) in the patient after allogeneic hematopoietic progenitor cell transplantation (allo-HPCT), and association of polycythemia with erytheroid.

A letter to the editor is presented which discusses a three-arm prospective and non-randomized study of clinical efficiency of an early discharge model (EDM) and home-care (HC) treatment for multiple myeloma (MM) being treated with high dose melphalan (HDM) with hematopoietic progenitor cell (HPC).